Alpha Tau Medical Ltd. has announced significant progress in its clinical research efforts with the recent FDA approval to expand its REGAIN trial for recurrent glioblastoma. This approval allows the company to increase patient enrollment from 10 to 20 participants, which may lead to more comprehensive data on the efficacy of its innovative treatment, Alpha DaRT.

The REGAIN trial is crucial for Alpha Tau, as glioblastoma is known as the most common malignant primary brain tumor in the U.S., and treatment options are limited. The expansion of this trial is expected to provide valuable insights that could support future regulatory submissions for Alpha DaRT.

Background

Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company focused on developing and commercializing Alpha DaRT, a novel treatment for solid tumors. The company operates under the SIC code 3841, which pertains to Surgical & Medical Instruments & Apparatus. It trades on the Nasdaq under the tickers DRTS and DRTSW.

Recent filings include a series of 6-K forms, with the latest dated October 19, 2026, detailing the FDA approval and the trial expansion.

What the Filing Says

The filing states, "the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) supplement expanding its U.S. REGAIN trial." This expansion will allow the trial to enroll up to 20 patients and includes new endpoints such as progression-free survival and quality-of-life assessments.

Impact

This FDA approval may significantly affect patients with recurrent glioblastoma, as it allows for a more extensive clinical dataset that could lead to improved treatment options. The trial's findings will also be presented at the Society for Neuro-Oncology (SNO) annual meeting, potentially influencing the broader oncology community and competitors in the medical instruments industry.

What's Next

The filing does not specify what happens next, but the upcoming presentation at the SNO annual meeting in November will likely be a key event for Alpha Tau as it seeks to share its findings and advance its clinical program.